RedHill Biopharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
RedHill Biopharma Ltd. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue8.046.5361.8085.7664.366.298.36
Cost of Revenue3.193.4633.34-49.4136.892.262.84
Gross Profit4.853.0728.4636.3527.474.035.52
Operating Expenses
Research & Development1.593.537.2829.5016.4917.4224.86
Selling, General & Administrative15.5230.9864.0387.9974.6630.2519.99
Operating Expenses17.1134.5071.31134.15103.9147.6744.85
Operating Income-12.25-31.43-42.84-97.80-76.44-43.64-39.33
Other Income/Expense
Interest Income0.130.090.140.050.180.000.28
Interest Expense-0.060.37-41.33-16.57-12.450.000.00
Other Income/Expense6.3057.5112.41-0.07-0.09-3.500.27
Income
Income Before Tax-8.2723.92-71.67-97.74-76.17-42.30-38.82
Income Tax Expense0.000.000.000.000.000.000.00
Net Income-8.2723.92-71.67-97.74-76.17-42.30-38.82
Net Income - Continuous Operations-8.2723.92-71.67-97.740.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-12.1626.27-34.69-95.83-74.46-41.31-38.73
EBIT-12.2524.28-42.84-97.74-76.17-42.30-38.82
Depreciation & Amortization0.101.998.1518.15-1.56-0.890.00
Earnings Per Share
Basic EPS-7.00100.00-1163.00-8.00-6.00-
Diluted EPS-7.00100.00-1163.00-8.00-6.00-
Basic Shares Outstanding1.230.260.06465.279.117.420.00
Diluted Shares Outstanding1.230.260.06465.459.117.420.00